~~<i id='5D88FF960E'><strike id='5D88FF960E'><tt id='5D88FF960E'><pre id='5D88FF960E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

knowledge

author：fashion 2025-10-01 01:51:03 - browse：85684

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Hospitals consider fixing cancer drug shortages on their own

entertainment

focus

explore

focus

KeishaOkaforforSTATClinicaltrialsarecriticaltoadvancinglifesavingmedicationsandtreatments.ButtheU.S.

WSS

How medical schools plan to diversify without affirmative action

New weight loss drugs vying to be the next Wegovy or Mounjaro

Private equity could exacerbate cardiology's overuse problem, experts fear

New Covid vaccine is recommended for everyone 6 months or older

How medical schools plan to diversify without affirmative action

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

focus

knowledge

entertainment

Supreme Court strikes down use of affirmative action

FDA panel endorses Alnylam’s heart drug — after picking it apart

Drug repurposing or repositioning? The language matters

Private equity could exacerbate cardiology's overuse problem, experts fear

Activists slam private health insurers over coverage restrictions

FDA proposes changes to key medical devices approval pathway

Anesthesiologist group: stop taking Ozempic before surgery

Hospitals consider fixing cancer drug shortages on their own

What does generative AI mean for health care? We asked experts

How medical schools plan to diversify without affirmative action

focus

Food makers tried to stack nutrition panel with preferred experts

Will the IRA bring competition to the biologics market?

PEPFAR is under serious threat — and so is global health

How medical schools plan to diversify without affirmative action

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Hospitals consider fixing cancer drug shortages on their own

focus

focus

explore

focus